New Brunswick, NJ — The Research & Development Council of New Jersey presented its 2016 Edison Patent Award to a Rutgers professor, two former faculty members at the university and a retired research staffer at the council’s annual awards event on November 3.
Raphael Mannino and Ruying Lu, former researchers in the Department of Pathology and Laboratory Medicine at the Rutgers New Jersey Medical School, now both at Matinas BioPharma, was honored for a new drug delivery technology they invented.
The technology, which is termed “cochleates made with soy phosphatidylserine,” uses a unique lipid-crystal nano-particle to encapsulate existing drugs and other biologically active compounds, which makes them safer, less toxic, orally bioavailable and more tolerable for patients.
The technology is being developed and commercialized by Matinas BioPharma of Bedminster Township, which was founded in 2012.
Raphael Mannino and Ruying Lu, former researchers in the Department of Pathology and Laboratory Medicine at the Rutgers New Jersey Medical School, now both at Matinas BioPharma, was honored for a new drug delivery technology they invented.
The technology, which is termed “cochleates made with soy phosphatidylserine,” uses a unique lipid-crystal nano-particle to encapsulate existing drugs and other biologically active compounds, which makes them safer, less toxic, orally bioavailable and more tolerable for patients.
The technology is being developed and commercialized by Matinas BioPharma of Bedminster Township, which was founded in 2012.
Joseph Goffreda, a professor in the Department of Plant Biology and Pathology at Rutgers–New Brunswick, also received the Edison Patent Award. One of his former colleagues will share the honor: Anna Voordeckers, a retired research staff member.
They developed a patented hybrid peach variety marketed under the name TangOs® that is able to thrive in New Jersey’s sometimes difficult growing conditions, while maintaining the combination of peach attributes attractive to both consumers and commercial producers.
“These inventors’ accomplishments are examples of the extremely valuable innovations that have been developed at Rutgers over its 250-year history,” said Christopher J. Molloy, Rutgers senior vice president for research and economic development.
“The unique approach to drug delivery invented by Raphael Mannino and Ruying Lu has great promise for improving the efficacy of numerous medications, and ultimately the lives of many patients around the world,” Dr. Molloy said.
“The work by Joseph Goffreda and Anna Voordeckers is among the latest in a long line of valuable innovations that Rutgers has shared with New Jersey growers, who are key contributors to our state’s economy,” Dr. Molloy added.
Goffreda, who has 26 other patents for apples, apricots, nectarines and peaches, has led the Rutgers tree fruit breeding program since 1989.
The R&D Council’s 37th Patent Award Ceremony and Reception will be held at the Liberty Science Center in Jersey City. The center is home to the nation’s largest IMAX Theater, where a short original film will pay tribute to the honored individuals and the patents of the inventors.
About Rutgers
Rutgers, The State University of New Jersey, is a leading national research university. Established in 1766 and celebrating a milestone 250th anniversary in 2016, it is the eighth oldest higher education institution in the nation. More than 69,000 students and 22,000 faculty and staff learn, work and serve the public at sites across New Jersey and around the world. Rutgers–New Brunswick is the state’s only public institution in the prestigious Association of American Universities.
Rutgers belongs to the Big Ten Academic Alliance, which comprises 14 world-class research universities. It is among the top 20 public U.S. universities for total R&D funding, and over the past two years has seen a 22 percent increase in research grants and sponsored programs, up to $637.9 million in FY2016.
The Office of Research and Economic Development is a central point for industry to access Rutgers and offers a website for industry: businessportal.rutgers.edu.
About Matinas BioPharma
Matinas BioPharma is a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective broad spectrum therapeutics for the treatment of serious and life-threatening infections.
The Company's proprietary, disruptive technology utilizes lipid-crystal nano-particle cochleates to nano-encapsulate existing drugs, making them safer, more tolerable, less toxic and orally bioavailable.
The Company's lead drug candidate is MAT2203, an orally-administered, encochleated formulation of amphotericin B (a broad spectrum fungicidal agent).
The Company has an open Investigational New Drug (IND) application for MAT2501, which is an orally-administered, encochleated formulation of amikacin (a broad spectrum aminoglycoside antibiotic agent) for acute bacterial infections, including non-tuberculous mycobacterium (NTM) and multi-drug resistant gram negative bacterial infections.
The Company's lead anti-infective product candidates, MAT2203 and MAT2501, position Matinas BioPharma to become a leader in the safe and effective delivery of anti-infective therapies utilizing its proprietary lipid-crystal nano-particle cochleate formulation technology.
For more information, please visit www.matinasbiopharma.com and connect with the Company on Twitter, LinkedIn, Facebook, and Google+.
They developed a patented hybrid peach variety marketed under the name TangOs® that is able to thrive in New Jersey’s sometimes difficult growing conditions, while maintaining the combination of peach attributes attractive to both consumers and commercial producers.
“These inventors’ accomplishments are examples of the extremely valuable innovations that have been developed at Rutgers over its 250-year history,” said Christopher J. Molloy, Rutgers senior vice president for research and economic development.
“The unique approach to drug delivery invented by Raphael Mannino and Ruying Lu has great promise for improving the efficacy of numerous medications, and ultimately the lives of many patients around the world,” Dr. Molloy said.
“The work by Joseph Goffreda and Anna Voordeckers is among the latest in a long line of valuable innovations that Rutgers has shared with New Jersey growers, who are key contributors to our state’s economy,” Dr. Molloy added.
Goffreda, who has 26 other patents for apples, apricots, nectarines and peaches, has led the Rutgers tree fruit breeding program since 1989.
The R&D Council’s 37th Patent Award Ceremony and Reception will be held at the Liberty Science Center in Jersey City. The center is home to the nation’s largest IMAX Theater, where a short original film will pay tribute to the honored individuals and the patents of the inventors.
About Rutgers
Rutgers, The State University of New Jersey, is a leading national research university. Established in 1766 and celebrating a milestone 250th anniversary in 2016, it is the eighth oldest higher education institution in the nation. More than 69,000 students and 22,000 faculty and staff learn, work and serve the public at sites across New Jersey and around the world. Rutgers–New Brunswick is the state’s only public institution in the prestigious Association of American Universities.
Rutgers belongs to the Big Ten Academic Alliance, which comprises 14 world-class research universities. It is among the top 20 public U.S. universities for total R&D funding, and over the past two years has seen a 22 percent increase in research grants and sponsored programs, up to $637.9 million in FY2016.
The Office of Research and Economic Development is a central point for industry to access Rutgers and offers a website for industry: businessportal.rutgers.edu.
About Matinas BioPharma
Matinas BioPharma is a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective broad spectrum therapeutics for the treatment of serious and life-threatening infections.
The Company's proprietary, disruptive technology utilizes lipid-crystal nano-particle cochleates to nano-encapsulate existing drugs, making them safer, more tolerable, less toxic and orally bioavailable.
The Company's lead drug candidate is MAT2203, an orally-administered, encochleated formulation of amphotericin B (a broad spectrum fungicidal agent).
The Company has an open Investigational New Drug (IND) application for MAT2501, which is an orally-administered, encochleated formulation of amikacin (a broad spectrum aminoglycoside antibiotic agent) for acute bacterial infections, including non-tuberculous mycobacterium (NTM) and multi-drug resistant gram negative bacterial infections.
The Company's lead anti-infective product candidates, MAT2203 and MAT2501, position Matinas BioPharma to become a leader in the safe and effective delivery of anti-infective therapies utilizing its proprietary lipid-crystal nano-particle cochleate formulation technology.
For more information, please visit www.matinasbiopharma.com and connect with the Company on Twitter, LinkedIn, Facebook, and Google+.
